Chimeric Therapeutics : Investor Presentation - Entitlement Offer

ersonal use only

CAPITAL RAISING PRESENTATION FEBRUARY 2022

DISCLAIMER

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Chimeric Therapeutics Limited ACN 638 835 828 (Company). In preparing this presentation, the Company did not take into account the

i	vestment objectives, financial situation and particular needs of any particular
i	vestor.
onlyFurther advice should be obtained from a professional investment adviser

before taking any action on any information dealt with in the presentation. useThose acting upon any information without advice do so entirely at their own

risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of

ersonalthem for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this

presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

1. Certain statements contained in this presentation, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.
2. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

2

INVESTMENT HIGHLIGHTS

use only

Rapid Growth

Fastest growing cell therapy pipeline in Australia with 7 novel assets in development

Innovative & Diversified Portfolio
Diversified portfolio leveraging both	T

Cell and NK cell innovation and individualized and off the shelf platforms

Extensive Clinical Development

4 planned clinical programs in 2022 and 8 planned clinical programs by 2023 in 10+ types of blood cancers and solid tumours

Capital Raising & Balance Sheet

Early Positive Clinical Signals

Initial positive ph. 1 clinical data in GBM with dose cohort 4 complete 2H22

Expedited Regulatory Pathway

Anticipated fast to market development with FDA registration from positive Phase 2 data

World Renowned Partners

Research collaborations with University of Pennsylvania and City of Hope- world renowned cell therapy centres

Proven Cell Therapy Experience

Industry leading management team with 40+ years of critical cell therapy expertise (incl 4 of 5 FDA approvals)

ersonal

Accelerated non-renounceable entitlement offer to raise up to approximately $18.1m at $0.17 per share with free attaching 1:1 listed option exercisable at $0.255 and expiring on 31 March 2024. A$31.5m pro-forma cash balance post raise. Key programs funded into 2023 and past Phase 1A GBM readout. Potential A$27.2m of additional funding from option exercise option.

CHIMERIC MANAGEMENT TEAM

GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION

ersonal use only

EXPERIENCE		EXPERTISE
40+ Experience		25+	Development
Years of Cell Therapy
			Programs

Jennifer	Dr Eliot	Dr Li	Elizabeth
CHOW	REN	TRAUPMAN
BOURK
Chief Executive	VP, Technical	Senior Director
Chief Business Officer
Officer	Operations	Project Leadership

PROVEN

4/5 Of the

FDA Approved

CAR T Cell Therapies

WORLD RENOWNED

ADVISORS AND COLLABORATORS

only	CELLULAR IMMUNOTHERAPY SCIENTIFIC ADVISORY BOARD
ersonal use	Chair, Cellular Therapeutics	Director, Center for	Director Translational Research,	Director, Cellular
	Cellular Therapy	Immune Effector Cell Therapies	Immunotherapy Clinic

RESEARCH COLLABORATORS

RESEARCH PARTNERS

17.